Under one in 10 patients eligible to benefit from obesity jabs including Wegovy have access to them, states the World Health Organization as it releases its inaugural guidance on the drugs.
Given over a billion individuals worldwide now living with obesity, it is calling for increased and just availability to GLP-1 medication.
Per projections, in excess of 2,000,000,000 could be living with obesity by 2030 without intervention.
"Our new guidelines affirms that obesity is a long-term condition that can be managed with comprehensive and lifelong treatment," remarked WHO director-general Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and supply-chain constraints are major barriers to widespread availability to the jabs that can assist patients in reducing substantial body mass, explains the body.
Weight-Loss Drug Shortage
Despite the current most favorable case, the production of such drugs would only suffice for about 100 million people – under 10% of eligible patients, per the WHO.
The advice urges governments and firms to widen access, through strategies such as patent sharing.
The intellectual property rights on semaglutide – the main ingredient of Novo Nordisk's Wegovy – is set to lapse in a number of nations in 2026.
How Obesity Jabs Function
GLP-1 drugs replicate a biological compound to delay gastric emptying, reduce hunger and boost feelings of fullness so users eat less.
Individuals typically see weight reduction after several weeks of beginning the regular doses.
Studies points to people may put most of the weight back on within a year of discontinuing the treatment, as their typical hunger come back.
Being above a healthy weight raises your risk for experiencing health problems, like type 2 diabetes, cardiovascular issues, stroke, and specific cancers.
Excess weight concerns individuals in all nations and was linked to 3.7 million deaths worldwide in 2024, as per the WHO.
